Cencora (COR) has seen significant gains in its stock, driven by successful earnings results, raised views for 2024, and it continues to be a top growth stock for the long term. Despite some inside sell-offs by the CEO Steven Collis and executive vice president Silvana Battaglia, the stock has proven resilient. However, Cencora faced a setback, falling due to the sell-off of its shares by Walgreens Boots Alliance. Despite this, Cencora continues to perform well and has hit numerous 52-week highs in recent times. The company's revenue fell short due to a weight-loss drug shortage, but they still managed to surpass Q3 earnings and revenue estimates. Analysts at Zacks Research and JPMorgan Chase raised earnings estimates and price targets, respectively, showing market confidence. The company announced a common share repurchase from Walgreens Boots Alliance in a strategic move. However, concerns linger about data breaches and the subsequent impact on individual's private information, although Cencora has issued notifications about the data stealage. Despite these challenges, potential growth is identified making Cencora a valuable asset for portfolios while being recognized as a company with great economics.
Cencora COR News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sun, 25 Aug 2024 04:32:48 GMT -
Rating 6
- Innovation 6
- Information 7
- Rumor 5
